Zenith Drugs Limited
Live Updates, GMP, Subscription Data, and Financial Details
IPO Overview
Listed
Dates
Feb 19 to Feb 22, 2024
Price Band
₹75-79
Current GMP
₹110 (39.23%)
Subscription
179.18 times
IPO Details
| IPO Date | February 19, 2024 to February 22, 2024 |
| Listing Date | Tuesday, February 27, 2024 |
| Face Value | ₹10 per share |
| Price Band | ₹75 to ₹79 per share |
| Lot Size | 1600 Shares |
| Total Issue Size | 5,148,800 shares (aggregating up to ₹40.68 Cr) |
| Fresh Issue | 5,148,800 shares (aggregating up to ₹40.68 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Share holding pre issue | 12,000,000 |
| Share holding post issue | 17,148,800 |
| Market Maker portion | 852,800 shares Gretex Share Broking |
IPO Date
February 19, 2024 to February 22, 2024
Listing Date
Tuesday, February 27, 2024
Face Value
₹10 per share
Price Band
₹75 to ₹79 per share
Lot Size
1600 Shares
Total Issue Size
5,148,800 shares (aggregating up to ₹40.68 Cr)
Fresh Issue
5,148,800 shares (aggregating up to ₹40.68 Cr)
Issue Type
Book Built Issue IPO
Listing At
NSE SME
Share holding pre issue
12,000,000
Share holding post issue
17,148,800
Market Maker portion
852,800 shares Gretex Share Broking
IPO Subscription Details
| Anchor Investors | 1 |
| Market Maker | 1 |
| Qualified Institutions | 106.72 |
| Non-Institutional Buyers* | 368.77 |
| Retail Investors | 139.28 |
| Total ** | 179.18 |
Anchor Investors
1
Market Maker
1
Qualified Institutions
106.72
Non-Institutional Buyers*
368.77
Retail Investors
139.28
Total **
179.18
Day Wise Sub
| Day | QIB | NII* | Retail | Total |
|---|---|---|---|---|
| Day 1 Feb 19, 2024 | 0.00 | 0.99 | 3.42 | 1.92 |
| Day 2 Feb 20, 2024 | 3.53 | 2.50 | 9.41 | 6.25 |
| Day 3 Feb 21, 2024 | 3.54 | 7.98 | 19.42 | 12.43 |
| Day 4 Feb 22, 2024 | 106.72 | 368.77 | 139.28 | 179.18 |
DayDay 1
Feb 19, 2024
QIB0.00
NII*0.99
Retail3.42
Total1.92
DayDay 2
Feb 20, 2024
QIB3.53
NII*2.50
Retail9.41
Total6.25
DayDay 3
Feb 21, 2024
QIB3.54
NII*7.98
Retail19.42
Total12.43
DayDay 4
Feb 22, 2024
QIB106.72
NII*368.77
Retail139.28
Total179.18
Day Wise GMP
| Date | Price | GMP | Estimate List Price |
|---|---|---|---|
| 27-02-2024 | 79.00 | 35 (44.3%) | 114 |
| 26-02-2024 | 79.00 | 35 (44.3%) | 114 |
| 25-02-2024 | 79.00 | 40 (50.63%) | 119 |
| 24-02-2024 | 79.00 | 40 (50.63%) | 119 |
| 23-02-2024 | 79.00 | 40 (50.63%) | 119 |
| 22-02-2024 | 79.00 | 20 (25.32%) | 99 |
| 21-02-2024 | 79.00 | 20 (25.32%) | 99 |
| 20-02-2024 | 79.00 | 17 (21.52%) | 96 |
| 19-02-2024 | 79.00 | 14 (17.72%) | 93 |
| 18-02-2024 | 79.00 | 14 (17.72%) | 93 |
| 17-02-2024 | 79.00 | 12 (15.19%) | 91 |
| 16-02-2024 | 79.00 | 7 (8.86%) | 86 |
| 15-02-2024 | 79.00 | 0 (0%) | 79 |
| 14-02-2024 | 79.00 | 0 (0%) | 79 |
| 13-02-2024 | 79.00 | 0 (0%) | 79 |
Date27-02-2024
Price79.00
GMP35 (44.3%)
Estimate List Price114
Date26-02-2024
Price79.00
GMP35 (44.3%)
Estimate List Price114
Date25-02-2024
Price79.00
GMP40 (50.63%)
Estimate List Price119
Date24-02-2024
Price79.00
GMP40 (50.63%)
Estimate List Price119
Date23-02-2024
Price79.00
GMP40 (50.63%)
Estimate List Price119
Date22-02-2024
Price79.00
GMP20 (25.32%)
Estimate List Price99
Date21-02-2024
Price79.00
GMP20 (25.32%)
Estimate List Price99
Date20-02-2024
Price79.00
GMP17 (21.52%)
Estimate List Price96
Date19-02-2024
Price79.00
GMP14 (17.72%)
Estimate List Price93
Date18-02-2024
Price79.00
GMP14 (17.72%)
Estimate List Price93
Date17-02-2024
Price79.00
GMP12 (15.19%)
Estimate List Price91
Date16-02-2024
Price79.00
GMP7 (8.86%)
Estimate List Price86
Date15-02-2024
Price79.00
GMP0 (0%)
Estimate List Price79
Date14-02-2024
Price79.00
GMP0 (0%)
Estimate List Price79
Date13-02-2024
Price79.00
GMP0 (0%)
Estimate List Price79
IPO Important Dates
| IPO Open Date | Monday, February 19, 2024 |
| IPO Close Date | Thursday, February 22, 2024 |
| Basis of Allotment | Friday, February 23, 2024 |
| Initiation of Refunds | Monday, February 26, 2024 |
| Credit of Shares to Demat | Monday, February 26, 2024 |
| Listing Date | Tuesday, February 27, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on February 22, 2024 |
IPO Open Date
Monday, February 19, 2024
IPO Close Date
Thursday, February 22, 2024
Basis of Allotment
Friday, February 23, 2024
Initiation of Refunds
Monday, February 26, 2024
Credit of Shares to Demat
Monday, February 26, 2024
Listing Date
Tuesday, February 27, 2024
Cut-off time for UPI mandate confirmation
5 PM on February 22, 2024
IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1600 | ₹126,400 |
| Retail (Max) | 1 | 1600 | ₹126,400 |
| HNI (Min) | 2 | 3,200 | ₹252,800 |
ApplicationRetail (Min)
Lots1
Shares1600
Amount₹126,400
ApplicationRetail (Max)
Lots1
Shares1600
Amount₹126,400
ApplicationHNI (Min)
Lots2
Shares3,200
Amount₹252,800
Financial Information
| Period Ended | 30 Sep 2023 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Period Ended | 30 Sep 2023 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 11,249.04 | 9,793.83 | 6,858.47 |
| Revenue | 6,948.43 | 11,569.65 | 9,266.63 |
| Profit After Tax | 539.38 | 515.29 | 312.86 |
| Net Worth | 2,264.96 | 1,724.42 | 1,209.09 |
| Reserves and Surplus | 1,064.96 | 1,684.42 | 1,169.09 |
| Total Borrowing | 2,902.81 | 2,605.03 | 1,880.86 |
Period EndedPeriod Ended
30 Sep 202330 Sep 2023
31 Mar 202331 Mar 2023
31 Mar 202231 Mar 2022
Period EndedAssets
30 Sep 202311,249.04
31 Mar 20239,793.83
31 Mar 20226,858.47
Period EndedRevenue
30 Sep 20236,948.43
31 Mar 202311,569.65
31 Mar 20229,266.63
Period EndedProfit After Tax
30 Sep 2023539.38
31 Mar 2023515.29
31 Mar 2022312.86
Period EndedNet Worth
30 Sep 20232,264.96
31 Mar 20231,724.42
31 Mar 20221,209.09
Period EndedReserves and Surplus
30 Sep 20231,064.96
31 Mar 20231,684.42
31 Mar 20221,169.09
Period EndedTotal Borrowing
30 Sep 20232,902.81
31 Mar 20232,605.03
31 Mar 20221,880.86
Key Performance Indicator
| ROE | 35.13% |
| ROCE | 37.29% |
| Debt/Equity | 1.51 |
| RoNW | 29.88% |
| P/BV | 5.5 |
| EPS (Rs) | 4.29 |
ROE
35.13%
ROCE
37.29%
Debt/Equity
1.51
RoNW
29.88%
P/BV
5.5
EPS (Rs)
4.29
IPO Reservation
| Anchor Investor Shares Offered | 1,288,000 (25.02%) |
| Market Maker Shares Offered | 852,800 (16.56%) |
| QIB Shares Offered | 859,200 (16.69%) |
| NII (HNI) Shares Offered | 644,800 (12.52%) |
| Retail Shares Offered | 1,504,000 (29.21%) |
| Total Shares Offered | 5,148,800 (100%) |
Anchor Investor Shares Offered
1,288,000 (25.02%)
Market Maker Shares Offered
852,800 (16.56%)
QIB Shares Offered
859,200 (16.69%)
NII (HNI) Shares Offered
644,800 (12.52%)
Retail Shares Offered
1,504,000 (29.21%)
Total Shares Offered
5,148,800 (100%)
Information about company
Incorporated in 2000, Zenith Drugs Limited is a pharmaceutical company specialising in manufacturing and trading high-quality, affordable medicines, including generic drugs.
The company adheres to WHO-GMP guidelines and has received the ISO 9001:2015 certification from a respected EuroUK certification body, demonstrating its commitment to quality.
The product portfolio of the company includesÂ
ORS Powder;
Liquid Orals;
Ointments;
Liquid Externals; and
Capsules
The Food & Drugs Administration has approved over 600 products, of which 325 are currently in production.
The company is in the process of setting up a new manufacturing facility in Village Muradpura, Depalpur, Indore, Madhya Pradesh.
The company supplies its products to countries such as Costa Rica in Central America and the Caribbean and Pacific regions, Malawi, Mauritius, Mozambique, Sudan, Tanzania, Bhutan , Cambodia in Southeast Asia, Tajikistan, Liberia, Sierra Leone, and Conakry.
Zenith Drugs Limited specializes in third-party manufacturing, also known as white label manufacturing, for esteemed pharmaceutical companies such as Ajanta Pharma, Bio Medical Laboratories, and Zest Pharma, among others.
There are currently 89 employees as of March 31, 2023 - 61 on payroll and 28 on contract.
Disclaimer
All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application.
No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever
Please read all Tearms and conditions , and agree to use the App